The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 01, 2020

Filed:

Jan. 11, 2019
Applicant:

Florida Atlantic University Board of Trustees, Boca Raton, FL (US);

Inventors:

Salvatore D. Lepore, Delray Beach, FL (US);

Kenneth Dawson-Scully, Boca Raton, FL (US);

Elijah J. St. Germain, Davie, FL (US);

Samantha L. Maki, Delray Beach, FL (US);

Wesley L. Bollinger, Dallas, TX (US);

Nadia K. Sial, Boca Raton, FL (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/192 (2006.01); A61K 31/191 (2006.01); C07C 69/753 (2006.01); C07C 67/03 (2006.01); A61P 25/00 (2006.01); A61P 25/06 (2006.01); A61P 25/28 (2006.01); A61P 9/04 (2006.01); C07C 62/34 (2006.01); C07C 69/18 (2006.01);
U.S. Cl.
CPC ...
C07C 69/753 (2013.01); A61P 25/00 (2018.01); C07C 62/34 (2013.01); C07C 67/03 (2013.01); C07C 69/18 (2013.01); C07C 2602/44 (2017.05); C07C 2602/46 (2017.05);
Abstract

Neuroprotective compounds for reducing neurological damage due to cellular stress in an individual are of Formula 1: or an enantiomer, diastereomer, racemic mixture or a pharmaceutically acceptable salt thereof, wherein: Ar=aryl; Y=aryl substituent (ortho, meta, or para) selected from the group consisting of: alkyl, alkyloxy, alkylamino, RRN, and halo; X═O, N, or S; R═H, alkyl, aryl, OH, alkyloxy, aryloxy, NH, alkylamino, RRN, or arylamino; Rand R=alkylcarbonyl, arylcarbonyl, alkyl, or H, individually; R=arylCH═CH, alkylCH═CH, alkyl; R═H, alkyl, or aryl; and Rand R=alkyl, individually. Methods of reducing neurological damage due to cellular stress in an individual include administering to the individual during or after the cellular stress a neuroprotective compound of Formula I in a therapeutically effective amount to restore synaptic function during or after the cellular stress.


Find Patent Forward Citations

Loading…